Search

Your search keyword '"Dev, Harveer"' showing total 140 results
Start Over Author "Dev, Harveer"
140 results on '"Dev, Harveer"'

3. 53BP1 and double-strand break repair pathway choice in cancer

Author

Dev, Harveer Singh and Jackson, Stephen Phillip

Subjects
572.8, DNA repair, BRCA1, 53BP1, Shieldin, Cancer, PARP inhibitor, Olaparib, Homologous recombination, Non-homologous end-joining, Double-strand break repair, Repair pathway choice
Abstract

The cellular response to DNA double-strand breaks (DSB) is principally the result of two competing repair pathways. The Tumour Protein P53 Binding Protein 1 (TP53BP1) gene product plays a central role in DSB repair pathway choice, promoting non-homologous end-joining (NHEJ) and counteracting homologous recombination (HR). As with all DNA damage response (DDR) proteins, cell-cycle regulation of 53BP1 is critical to its function. The inappropriate activity of 53BP1 in mitosis, during which most of the DDR is inactivated to preserve genome stability, has been shown to have adverse effects on cell division that are characteristic of cancers. We explored the consequences of replication stress, associated with oncogene activity, and the impact of aberrantly active 53BP1 in mitosis. This work reveals interference with normal mitotic mechanisms for detecting and resolving stalled replication intermediates; most evidently manifest as reduced mitotic DNA synthesis (MiDAS), and increased accumulation of acentric micronuclei and G1 nuclear bodies. We propose that the functional sequestration of TOPBP1 may be responsible for these chromosomal mis-segregation defects. The mechanism by which 53BP1 (together with RIF1 and MAD2L2) promote NHEJ remains elusive. Genome instability in HR-defective cancers, principally those harbouring a mutation in BRCA1, can be rescued by the concomitant loss of either 53BP1, RIF1 or MAD2L2. This phenomenon has relevance for the development of PARP (Poly(ADP-ribose) polymerase) inhibitor resistance, now being used in BRCA1-deficient breast, ovarian and prostate cancers based on the principle of 'synthetic lethality'. As part of a search for other resistance mechanisms, we identified the shieldin complex (SHLD1/C20orf196 and SHLD2/FAM35A) that when lost suppressed PARP inhibitor sensitivity in BRCA1-deficient cancer cells. We demonstrate that SHLD1/2 represent the terminal end-effectors of the 53BP1-RIF1-MAD2L2 axis, supporting NHEJ activity. We identified three OB-fold domains in SHLD2/FAM35A, that bind single-stranded DNA and are necessary for NHEJ. Loss of SHLD1 or SHLD2 (SHLD1/2) caused a hyper-resection phenotype, and which, in the absence of BRCA1 was associated with rescuing RAD51 loading. Downregulation in SHLD1/2 expression was also associated with intrinsic and acquired resistance across a panel of BRCA1-deficient patient-derived xenograft models. Promisingly, this mechanism may impart an acquired vulnerability to cisplatin or radiotherapy. Thus, we have characterised a critical component of the 53BP1 axis which is deterministic in repair pathway choice and carries implications for the treatment of cancers.

Published
2019
Full Text
View/download PDF

4. A comparative study of peri-operative outcomes for 100 consecutive post-chemotherapy and primary robot-assisted and open retroperitoneal lymph node dissections

Author

Lloyd, Paul, Hong, Anne, Furrer, Marc A., Lee, Elaine W. Y., Dev, Harveer S., Coret, Maurice H., Adshead, James M., Baldwin, Peter, Knight, Richard, Shamash, Jonathan, Alifrangis, Constantine, Stoneham, Sara, Mazhar, Danish, Wong, Han, Warren, Anne, Tran, Ben, Lawrentschuk, Nathan, Neal, David E., and Thomas, Benjamin C.

Published
2022
Full Text
View/download PDF

21. Ultrasensitive Detection of Circulating Tumour DNA enriches for Patients with a Greater Risk of Recurrence of Clinically Localised Prostate Cancer

Author

Pope, Bernard, Park, Gahee, Lau, Edmund, Belic, Jelena, Lach, Radoslaw, George, Anne, McCoy, Patrick, Nguyen, Anne, Grima, Corrina, Campbell, Bethany, Jung, Chol-hee, Ditter, Emma-Jane, Zhao, Hui, Wedge, David C., Brewer, Daniel S., Lynch, Andy G., Dev, Harveer, Gnanpragasam, Vincent J., Rosenfeld, Nitzan, Hovens, Christopher M., Corcoran, Niall M., and Massie, Charles E.

Published
2024
Full Text
View/download PDF

22. Shieldin complex promotes DNA end-joining and counters homologous recombination in BRCA1-null cells

Author

Dev, Harveer, Chiang, Ting-Wei Will, Lescale, Chloe, de Krijger, Inge, Martin, Alistair G., Pilger, Domenic, Coates, Julia, Sczaniecka-Clift, Matylda, Wei, Wenming, Ostermaier, Matthias, Herzog, Mareike, Lam, Jonathan, Shea, Abigail, Demir, Mukerrem, Wu, Qian, Yang, Fengtang, Fu, Beiyuan, Lai, Zhongwu, Balmus, Gabriel, Belotserkovskaya, Rimma, Serra, Violeta, O’Connor, Mark J., Bruna, Alejandra, Beli, Petra, Pellegrini, Luca, Caldas, Carlos, Deriano, Ludovic, Jacobs, Jacqueline J. L., Galanty, Yaron, and Jackson, Stephen P.

Published
2018
Full Text
View/download PDF

38. ASCERTAIN: An open-label, randomized, phase 1, window-of-opportunity study to investigate the biological effects of AZD5305 and darolutamide alone or in combination in men with prostate cancer eligible for radical prostatectomy.

Author

Pacey, Simon, Chi, Kim N., Azad, Arun, Mehra, Niven, Dev, Harveer, Gleave, Martin, Planas, Jacques, Warren, Anne, Harrington, Elizabeth, Albertella, Mark, Squatrito, Massimo, Moore, Luiza, Zhou, TJ, Womersley, Lynsey, Sugibayashi, Ko, Cosulich, Sabina, de Paula, Bruno, Lukacs, Edit, and Mateo, Joaquin

Published
2024
Full Text
View/download PDF

40. Identifying Prostate Cancer-Specific Signatures Through Unbiased Capture of Methylated Cell-Free DNA

Author

Lleshi, Ermira, primary, Milne-Clark, Toby, additional, Lee Yu, Henson, additional, Martin, Henno, additional, Hanson, Robert, additional, Lach, Radoslaw, additional, Rossi, Sabrina, additional, Flewitt, Andrew, additional, Lynch, Andy G., additional, Gnanapragasam, Vincent, additional, Massie, Charlie, additional, and Dev, Harveer, additional

Published
2023
Full Text
View/download PDF

44. Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer

Author

Asim, Mohammad, Tarish, Firas, Zecchini, Heather I., Sanjiv, Kumar, Gelali, Eleni, Massie, Charles E., Baridi, Ajoeb, Warren, Anne Y., Zhao, Wanfeng, Ogris, Christoph, McDuffus, Leigh-Anne, Mascalchi, Patrice, Shaw, Greg, Dev, Harveer, Wadhwa, Karan, Wijnhoven, Paul, Forment, Josep V., Lyons, Scott R., Lynch, Andy G., O’Neill, Cormac, Zecchini, Vincent R., Rennie, Paul S., Baniahmad, Aria, Tavaré, Simon, Mills, Ian G., Galanty, Yaron, Crosetto, Nicola, Schultz, Niklas, Neal, David, and Helleday, Thomas

Published
2017
Full Text
View/download PDF

46. A comparative study of peri-operative outcomes for 100 consecutive post-chemotherapy and primary robot-assisted and open retroperitoneal lymph node dissections

Author

Lloyd, Paul, primary, Hong, Anne, additional, Furrer, Marc A., additional, Lee, Elaine W. Y., additional, Dev, Harveer S., additional, Coret, Maurice H., additional, Adshead, James M., additional, Baldwin, Peter, additional, Knight, Richard, additional, Shamash, Jonathan, additional, Alifrangis, Constantine, additional, Stoneham, Sara, additional, Mazhar, Danish, additional, Wong, Han, additional, Warren, Anne, additional, Tran, Ben, additional, Lawrentschuk, Nathan, additional, Neal, David E., additional, and Thomas, Benjamin C., additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results